^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    1d
    CheckMate 76K: Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma (clinicaltrials.gov)
    P3, N=790, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Jun 2027 --> Nov 2026
    Trial completion date
    |
    Opdivo (nivolumab)
    1d
    Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies (clinicaltrials.gov)
    P1/2, N=40, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P1/2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    AiRuiKa (camrelizumab) • famitinib (SHR 1020)
    1d
    FIDELIO: Enfortumab Vedotin + Pembrolizumab Induction to Spare the Bladder in MIBC (clinicaltrials.gov)
    P2, N=56, Not yet recruiting, The Netherlands Cancer Institute
    New P2 trial
    |
    Keytruda (pembrolizumab) • Padcev (enfortumab vedotin-ejfv)
    1d
    The Seven Trial: Exploiting the Unfolded Protein Response (clinicaltrials.gov)
    P1, N=6, Terminated, HonorHealth Research Institute | Trial completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; The study was terminated early per the recommendation of the Data and Safety Monitoring Board (DSMB) after a planned interim analysis met pre-specified criteria for futility.
    Trial completion date • Trial termination • Trial primary completion date
    |
    cisplatin • gemcitabine • albumin-bound paclitaxel • balstilimab (AGEN2034) • botensilimab (AGEN1181) • celecoxib oral • chloroquine phosphate
    1d
    Evaluation of Esophagogastric Cancer Treatment With Nivolumab in Daily Clinical Practice (clinicaltrials.gov)
    P=N/A, N=726, Active, not recruiting, Bristol-Myers Squibb
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Opdivo (nivolumab)
    1d
    STAR-SCLC: Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • carboplatin • Tyvyt (sintilimab) • etoposide IV
    1d
    Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer (clinicaltrials.gov)
    P2, N=26, Active, not recruiting, National Cancer Institute (NCI) | N=16 --> 26
    Enrollment change
    |
    CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • PRGN-2009
    1d
    CA224-056: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, Dan Zandberg | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Jul 2026 --> Oct 2027
    Trial completion date • Trial primary completion date
    |
    LAG3 (Lymphocyte Activating 3)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • relatlimab (BMS-986016)
    1d
    Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) (clinicaltrials.gov)
    P1/2, N=1200, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • docetaxel • Lenvima (lenvatinib) • enzalutamide • abiraterone acetate • etoposide IV • prednisone • dexamethasone • Welireg (belzutifan) • vibostolimab/pembrolizumab (MK-7684A)
    1d
    Balancing Access and Value in Multi-Indication Medicines: Implications of PD-L1 Broad Listings in Australia. (PubMed, Pharmacoeconomics)
    In 2025, Australia's Pharmaceutical Benefits Advisory Committee adopted a novel broad cancer listing on the Pharmaceutical Benefits Schedule for nivolumab, ipilimumab and pembrolizumab. We suggest that while a broad listing represents a pragmatic response to the growing prevalence of multi-indication medicines, it entails important trade-offs between access, transparency and value alignment. These design considerations are likely to be relevant for other jurisdictions considering similar reimbursement reforms.
    Review • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Yervoy (ipilimumab)
    1d
    Mutant KRAS peptide vaccine with dual checkpoint blockade in metastatic colorectal cancer: a phase I trial. (PubMed, Nat Commun)
    In this single-arm, phase I study (NCT04117087), we evaluated mKRAS-VAX, a pooled mutant KRAS (mKRAS) peptide vaccine targeting six KRAS mutations with nivolumab and ipilimumab in 13 patients with pretreated metastatic MMRp/MSS CRC. mKRAS-VAX elicited an increase in tumor-specific mKRAS-reactive T-cells in 8/12 biomarker-evaluable patients (75%) by direct ex vivo IFNγ ELISpot and in 12 patients (100%) following in vitro expansion. Our findings support further development of mKRAS vaccines with ICIs for advanced MMRp/MSS CRC.
    P1 data • Journal • Checkpoint inhibition • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • IFNG (Interferon, gamma)
    |
    KRAS mutation
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • KRAS peptide vaccine
    1d
    Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P2, N=27, Recruiting, Xijing Hospital | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    Loqtorzi (toripalimab-tpzi) • albumin-bound paclitaxel • cyclophosphamide • epirubicin